S'abonner

Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study - 25/03/21

Doi : 10.1016/S1473-3099(20)30474-6 
Thomas Waterfield, PhD a, c, , Juli-Ann Maney, MBBCh b, Derek Fairley, PhD c, f, Mark D Lyttle, MBChB h, i, James P McKenna, PhD f, Damian Roland, PhD j, k, Michael Corr, MBBCh g, Lisa McFetridge, PhD d, Hannah Mitchell, PhD d, Kerry Woolfall, PhD l, Fiona Lynn, PhD e, Bethany Patenall, MSc m, Michael D Shields, MD c
on behalf of the

Paediatric Emergency Research in the UK and Ireland (PERUKI) Group

Amy Kitching, Matthew Rotheram, Gisela Robinson, Paula Brassey, Stuart Hartshorn, Rachel Wane, Mark Lyttle, Jo Dangerfield, Michael Hayes, Rebecca McFarlane, Helen Armstrong, Damian Roland, Sally Smith, Carl VanHeyningen, Sally Smith, Esther Wilson, Lisa Kehler, Christopher Gough, Fraser Scott, Claire Backhouse, Sylvester Gomes, Darryl Wood, Julie-Ann Maney, Graham Johnson, Steven Foster, Ben Bloom, Andrew Lancaster, Sebastian Gray, Shammi Ramlakhan, Sharryn Gardner, Sharon Floyd, Chris Cleaver, Susan MacFarlane, Claire Bell, Maggie Nyirenda, Jane Bayreuther, Asim Ijaz, Natalie Rogers, Sarah Wilson, Sarah Diment, Caroline Boulind, Kathryn Allison, Thomas Waterfield, Derek Fairley, James McKenna, Michael Corr, Lisa McFetridge, Hannah Mitchell, Kerry Woolfall, Fiona Lynn, Bethany Petenall, Michael Shields

a Emergency Department, Children’s Health Ireland at Temple Street, Dublin, Ireland 
b Emergency Department, Royal Belfast Hospital for Sick Children, Belfast, UK 
c Centre for Experimental Medicine, Wellcome Wolfson Institute of Experimental Medicine, Belfast, UK 
d Mathematical Sciences Research Centre, Queen’s University Belfast, Belfast, UK 
e School of Nursing and Midwifery, Centre for Evidence and Social Innovation, Queen’s University Belfast, Belfast, UK 
f Department of Microbiology, Belfast Health and Social Care Trust, Belfast, UK 
g Emergency Department, Belfast Health and Social Care Trust, Belfast, UK 
h Emergency Department, Bristol Royal Hospital for Children, Bristol, UK 
i Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK 
j SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK 
k Children’s Emergency Department, Leicester Royal Infirmary, Leicester, UK 
l Institute of Population Health and Society, University of Liverpool, Liverpool, UK 
m Department of Chemistry, University of Bath, Bath, UK 

* Correspondence to: Dr Thomas Waterfield, Centre for Experimental Medicine, Wellcome Wolfson Institute of Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UK Centre for Experimental Medicine Wellcome Wolfson Institute of Experimental Medicine Queen’s University Belfast Belfast BT9 7BL UK

Summary

Background

No previous studies have validated current clinical practice guidelines for the management of non-blanching rashes in children who have received meningococcal B and C vaccinations. The aim of this study was to evaluate the performance of existing clinical practice guidelines in the diagnosis of invasive meningococcal disease in children presenting with a fever and non-blanching rash in the UK.

Methods

The Petechiae in Children (PiC) study was a prospective, multicentre cohort study involving children (aged <18 years) presenting to 37 paediatric emergency departments in the UK with a fever (≥38°C) and a new-onset non-blanching rash or features suggestive of meningococcal infection. Children with pre-existing haematological conditions (ie, haematological malignancy, idiopathic thrombocytopenic purpura, or coagulopathy) or an existing diagnosis of Henoch-Schonlein purpura were excluded. Invasive meningococcal disease was confirmed by positive culture or a quantitative PCR test for Neisseria meningitidis from either blood or cerebrospinal fluid samples. The primary outcome was the performance of six tailored clinical practice guidelines from participating centres (London, Nottingham, Newcastle–Birmingham–Liverpool, Glasgow, Chester, and Bristol) and two clinical practice guidelines from the National Institutes for Health and Care Excellence (NICE; CG102 and NG51) in identifying children with invasive meningococcal disease, assessed by the sensitivity and specificity of each clinical practice guideline. This study is registered with ClinicalTrials.gov, NCT03378258.

Findings

Between Nov 9, 2017, and June 30, 2019, 1513 patients were screened, of whom 1329 were eligible and were included in the analysis. The median age of patients was 24 months (IQR 12–48). 1137 (86%) of 1329 patients had a blood test and 596 (45%) received parenteral antibiotics. 19 (1%) patients had confirmed meningococcal disease. All eight clinical practice guidelines had a sensitivity of 1·00 (95% CI 0·82–1·00) for identifying meningococcal disease. The specificities of NICE guidelines CG102 (0·01 [95% CI 0·01–0·02]) and NG51 (0·00 [0·00–0·00]) for identifying meningococcal disease were significantly lower than that of tailored clinical practice guidelines (p<0·0001). The best performing clinical practice guidelines for identifying meningococcal disease were the London (specificity 0·36 [0·34–0·39]) and Nottingham (0·34 [0·32–0·37]) clinical practice guidelines.

Interpretation

Invasive meningococcal disease is a rare cause of non-blanching rashes in children presenting to the emergency department in the UK. Current NICE guidelines perform poorly when compared with tailored clinical practice guidelines. These findings suggest that UK national guidance could be improved by shifting towards a tailored approach.

Funding

Public Health Agency.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 4

P. 569-577 - avril 2021 Retour au numéro
Article précédent Article précédent
  • Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial
  • Ananda S Bandyopadhyay, Chris Gast, Luis Rivera, Xavier Sáez-Llorens, M Steven Oberste, William C Weldon, John Modlin, Ralf Clemens, Sue Ann Costa Clemens, Jose Jimeno, Ricardo Rüttimann
| Article suivant Article suivant
  • Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review
  • Nadine K Kayiba, Doudou M Yobi, Evariste Tshibangu-Kabamba, Vo P Tuan, Yoshio Yamaoka, Brecht Devleesschauwer, Dieudonné M Mvumbi, Emile Okitolonda Wemakoy, Patrick De Mol, Georges L Mvumbi, Marie-Pierre Hayette, Angel Rosas-Aguirre, Niko Speybroeck

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.